Valion Bio (VBIO) Total Debt (2022)
Valion Bio (VBIO) posted quarterly Total Debt of $450000.0 for Q4 2022.
Valion Bio (VBIO) Total Debt (2022) Analysis & Trends
Valion Bio's Total Debt history runs 1 years deep, the most recent figure standing at $450000.0 for Q4 2022.
- In Q4 2022, Total Debt changed N/A year-over-year to $450000.0; the TTM figure through Dec 2022 stood at $450000.0 (changed N/A YoY), while the FY2022 annual figure was $450000.0, changed N/A from the prior year.
- Total Debt for Q4 2022 stood at $450000.0.
- The five-year high for Total Debt was $450000.0 in Q4 2022, with the low at $450000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.34 Bn |
| 10 | Valion Bio | 423,175.64 | -1.78 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 450,000.00 |